Literature DB >> 10196206

Transcomplementation between different types of respiration-deficient mitochondria with different pathogenic mutant mitochondrial DNAs.

D Takai1, K Isobe, J Hayashi.   

Abstract

Two cell lines were used for determination of whether interaction occurred between different types of respiration-deficient mitochondria. One was a respiration-deficient rho- cell line having mutant mitochondrial DNA (mtDNA) with a 5,196-base pair deletion including five tRNA genes (tRNAGly, Arg, Ser(AGY), Leu(CUN), His), DeltamtDNA5196, causing Kearns-Sayre syndrome. The other was a respiration-deficient syn- cell line having mutant mtDNA with an A to G substitution at 4,269 in the tRNAIle gene, mtDNA4269, causing fatal cardiomyopathy. The occurrence of mitochondrial interaction was examined by determining whether cybrids constructed by fusion of enucleated rho- cells with syn- cells became respiration competent by exchanging their tRNAs. No cybrids were isolated in selection medium, where only respiration-competent cells could survive, suggesting that no interaction occurred, or that it occurred so slowly that sufficient recovery of mitochondrial respiratory function was not attained by the time of selection. The latter possibility was confirmed by the observations that heteroplasmic cybrids with both mutant mtDNA4269 and DeltamtDNA5196 isolated without selection showed restored mitochondrial respiration activity. This demonstration of transcomplementation between different respiration-deficient mitochondria will help in understanding the relationship between somatic mutant mtDNAs and the roles of such mutations in aging processes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10196206     DOI: 10.1074/jbc.274.16.11199

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Mitochondrial DNA deletion mutations are concomitant with ragged red regions of individual, aged muscle fibers: analysis by laser-capture microdissection.

Authors:  Z Cao; J Wanagat; S H McKiernan; J M Aiken
Journal:  Nucleic Acids Res       Date:  2001-11-01       Impact factor: 16.971

2.  The evolution and role of mitochondrial fusion and fission in aging and disease.

Authors:  Axel Kowald; Thomas Bl Kirkwood
Journal:  Commun Integr Biol       Date:  2011-09-01

3.  Evolution of the mitochondrial fusion-fission cycle and its role in aging.

Authors:  Axel Kowald; Tom B L Kirkwood
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-06       Impact factor: 11.205

Review 4.  Why mitochondria must fuse to maintain their genome integrity.

Authors:  Sara Vidoni; Claudia Zanna; Michela Rugolo; Emmanuelle Sarzi; Guy Lenaers
Journal:  Antioxid Redox Signal       Date:  2013-03-28       Impact factor: 8.401

Review 5.  Mitochondrial subversion in cancer.

Authors:  Aditi Chatterjee; Santanu Dasgupta; David Sidransky
Journal:  Cancer Prev Res (Phila)       Date:  2011-05

Review 6.  Do mitochondria recombine in humans?

Authors:  A Eyre-Walker
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-11-29       Impact factor: 6.237

7.  Non-random mtDNA segregation patterns indicate a metastable heteroplasmic segregation unit in m.3243A>G cybrid cells.

Authors:  Anton K Raap; Roshan S Jahangir Tafrechi; Frans M van de Rijke; Angela Pyle; Carolina Wählby; Karoly Szuhai; Raimond B G Ravelli; René F M de Coo; Harsha K Rajasimha; Mats Nilsson; Patrick F Chinnery; David C Samuels; George M C Janssen
Journal:  PLoS One       Date:  2012-12-18       Impact factor: 3.240

Review 8.  Targeting microglial K(ATP) channels to treat neurodegenerative diseases: a mitochondrial issue.

Authors:  Manuel J Rodríguez; Margot Martínez-Moreno; Francisco J Ortega; Nicole Mahy
Journal:  Oxid Med Cell Longev       Date:  2013-06-16       Impact factor: 6.543

9.  Mitochondrial nucleoids maintain genetic autonomy but allow for functional complementation.

Authors:  Robert W Gilkerson; Eric A Schon; Evelyn Hernandez; Mercy M Davidson
Journal:  J Cell Biol       Date:  2008-06-23       Impact factor: 10.539

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.